Arcus Biosciences, Inc. (RCUS)
NYSE · Healthcare · Biotechnology
$24.74+1.23%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $3.1B
- 52-week range
- $13.71 – $31.74
- 52-week change
- +74.20%
- EPS (trailing)
- −$3.91
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Oct 27, 2026
Fiscal year to Dec 2025
- Revenue
- $247M (−4.26%)
- Net income
- −$353M
- Operating margin
- −156.3%
- Diluted EPS
- −$3.29
- Free cash flow
- −$484M
From the company’s annual report on SEC EDGAR.
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P.
Headquarters: Hayward, United States · 601 employees · arcusbio.com